Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...
Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements after treatment with the monoclonal antibody dupilumab. The disease improvements — as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results